Extract
The World Health Organization (WHO) recently endorsed a new definition of extensively drug-resistant tuberculosis (XDR-TB) and, for the first time, introduced the category of pre-XDR-TB [1]. Pre-XDR-TB is defined as multidrug resistance/rifampicin resistance (MDR/RR) in conjunction with resistance to any fluoroquinolone (levofloxacin or moxifloxacin), whereas the conditions for XDR-TB are now met by additional resistance to a group A drug (bedaquiline or linezolid) [1].
Abstract
The new definition of extensively drug resistant tuberculosis endorsed by WHO poses some challenges that must be addressed in a coordinated fashion by researchers, TB control stakeholders and assay developers https://bit.ly/3eAMU8B
Footnotes
P. Miotto, S. Niemann, S. Gagneux, C.U. Köser, C. Rodrigues and P.M.V. Rancoita are part of the New Diagnostic Working Group Task Force on NGS and DST of the STOP TB Partnership. D.M. Cirillo is co-chair of the of the New Diagnostic Working Group. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official position of the STOP TB Partnership.
Conflict of interest: R. Alagna has nothing to disclose.
Conflict of interest: A.M. Cabibbe has nothing to disclose.
Conflict of interest: P. Miotto has nothing to disclose.
Conflict of interest: F. Saluzzo has nothing to disclose.
Conflict of interest: C.U. Köser is a consultant for Becton Dickinson, the Foundation for Innovative New Diagnostics, the Stop TB Partnership and the TB Alliance; has worked as a consultant for QuantuMDx, the World Health Organization (WHO) Global TB Programme, and WHO Regional Office for Europe; gave a paid educational talk for Oxford Immunotec; had travel and accommodation expensed covered by Hain Lifescience to present at a meeting; and is an unpaid advisor to BioVersys and GenoScreen.
Conflict of interest: S. Niemann has nothing to disclose.
Conflict of interest: S. Gagneux has nothing to disclose.
Conflict of interest: C. Rodrigues has nothing to disclose.
Conflict of interest: P.M.V. Rancoita has nothing to disclose.
Conflict of interest: D.M. Cirillo has nothing to disclose.
- Received March 31, 2021.
- Accepted April 22, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org